动物胃食道逆流症市场－全球产业规模、份额、趋势、机会、预测：按产品、动物种类、给药途径、分销管道、地区和竞争格局划分，2021-2031年

全球动物胃食道逆流症市场预计将从 2025 年的 35.6 亿美元成长到 2031 年的 59.2 亿美元，复合年增长率达到 8.85%。

此细分市场包括专门用于缓解伴侣动物胃酸倒流的专用诊断工具和药物治疗，例如质子帮浦阻断剂和H2受体拮抗剂。推动这一成长的主要动力是宠物人性化的趋势。这导致饲主更愿意投资先进的兽医保健，同时也导致老年宠物胃肠道疾病的盛行率上升。正如美国宠物产品协会在2024年指出的那样，美国宠物行业的总支出达到1520亿美元，其中398亿美元用于兽医保健和产品，这表明饲主愿意为宠物的健康承担相当大的经济负担。

然而，长期兽医护理和特殊诊断程序的高昂费用对市场发展构成重大障碍。这些巨额费用令注重预算的宠物饲主望而却步，可能限制综合治疗方案的广泛实施，并减缓整个产业的成长速度。因此，价格敏感性仍然是一个重大挑战，阻碍了动物胃食道逆流症综合管理方案的推广，并减缓了市场扩张。

市场驱动因素

全球宠物饲养量的激增和宠物人性化的趋势正在从根本上改变人们对专业兽医护理的需求，尤其是对胃食道逆流（GERD）等慢性疾病的需求。随着饲主越来越将宠物视为家庭成员，他们更倾向于关注反流和吞嚥困难等令人痛苦的症状，并及时寻求兽医治疗。这种情感纽带推动了诊断和药物治疗方案使用量的增加，从而扩大了抑酸剂的市场。根据英国宠物食品协会发布的《2024年宠物数量》报告，英国约有1,720万户家庭饲养宠物，占总人口的60%。这导致需要治疗慢性消化系统疾病的患者群体庞大且持续成长。

此外，由于体重过重导致胃肠功能显着受损，饮食诱发和肥胖相关的逆流性疾病日益增多，这成为推动市场成长的关键临床催化剂。肥胖会增加腹内压，导致括约肌功能障碍和慢性胃酸逆流，需要长期服药。然而，由于饲主缺乏相关意识，早期治疗往往受阻。根据宠物肥胖预防协会于2024年5月发布的《2023年全国宠物体重和营养调查》，只有17%的狗饲主意识到他们的宠物超重，这与临床盛行率有显着差异。这种认知差距表明，随着诊断意识的提高，以及该行业强劲的经济基础，市场潜力巨大。例如，硕腾公司在2024年公布的2023年全年销售额为85亿美元。

市场挑战

长期兽医护理和特殊诊断程序的高昂费用是全球动物胃食道逆流（GERD）市场成长的主要障碍。准确诊断通常需要内视镜检查和特殊pH值监测等昂贵的检查，而有效治疗则需要长期服用质子帮浦阻断剂等药物。这些经济负担对价格敏感的宠物饲主来说是一大障碍，常常导致必要的诊断测试延误和维持治疗中断。因此，部分宠物得不到治疗，从而降低了潜在的市场收入。

这种经济负担也体现在近期的行业指标中，这些指标显示价格上涨正在影响消费者的行为。据美国兽医协会（AVMA）称，2024年对数千家诊所的数据分析显示，与前一年相比，宠物就诊量下降了2.3%，这一趋势主要归因于饲主因服务成本上涨而减少就诊次数。就诊量的下降直接阻碍了市场发展，减少了兽医诊断和治疗复杂胃肠道疾病的机会，从而抑制了反流性疾病药物的使用。

市场趋势

针对短头犬种量身定制的治疗通讯协定的采用，正在迅速改变全球动物胃食道逆流症市场的临床标准。兽医们日益认识到短头犬阻塞性气道症候群（BOAS）、食道裂孔疝气和慢性胃酸倒流之间的联繫，因此引入了将外科气道矫正与长期抑制胃酸分泌相结合的专门治疗方法。这种针对特异性犬种的治疗方法得益于扁脸犬种经久不衰的受欢迎程度，因为这些犬种在基因上比其他犬种需要更多的胃肠道护理。根据美国犬业俱乐部2024年3月报告，法国斗牛犬仍然是註册数量最多的犬种，註册数量高达98,500只，确保了需要这些针对性反流管理策略的患者数量稳定。

同时，治疗性胃肠道饮食和营养管理的广泛应用，正将治疗策略从依赖药物转向更全面、保守的方法。业界领导企业正积极拓展其产品线，提供易于消化、低脂的处方粮和肠道菌丛增强补充剂，旨在缓解逆流症状，改善食道动力，并避免长期用药带来的副作用。这一趋势反映了功能性保健产品在消化系统治疗中的辅助作用，这些产品可与标准质子帮浦阻断剂相辅相成。根据《宠物食品产业杂誌》（2024年2月刊）报道，普瑞纳Pro Plan兽用营养补充剂的销售额在2023年增长了22.6%，显示用于改善消化健康的营养干预措施正在迅速商业性。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：动物胃食道逆流症全球市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 产品类别（诊断、治疗、其他）
  • 动物种类（伴侣动物、家畜）
  • 给药途径（口服、注射）
  • 分销通路（兽医院/诊所、零售药局、电子商务）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美动物胃食道逆流症市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲动物胃食道逆流症市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区动物胃食道逆流症市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲动物胃食道逆流症市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲动物胃食道逆流症市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球动物胃食道逆流症市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale SA
• Boehringer Ingelheim International GmbH
• McNeil Consumer Pharmaceuticals Co.
• BioZyme, Inc.
• Annamaet Petfoods Inc.
• Hill's Pet Nutrition, Inc.
• Blue Buffalo Co., Ltd.

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Animal Gastroesophageal Reflux Disease Market is projected to expand from USD 3.56 Billion in 2025 to USD 5.92 Billion by 2031, achieving a CAGR of 8.85%. This market sector encompasses specialized diagnostic tools and pharmaceutical treatments, such as proton pump inhibitors and H2 receptor antagonists, specifically formulated to alleviate acid reflux in companion animals. Growth is primarily propelled by the pet humanization trend, which has fostered a greater willingness among owners to fund advanced veterinary healthcare, alongside an increasing prevalence of gastrointestinal ailments in aging pet populations. As highlighted by the American Pet Products Association in 2024, total U.S. pet industry spending hit $152 billion, with $39.8 billion directed toward veterinary care and products, demonstrating the substantial financial dedication owners have toward animal well-being.

However, the high expenses linked to long-term veterinary care and specialized diagnostic procedures pose a significant obstacle to market progression. These substantial costs can establish a barrier for budget-conscious pet owners, potentially restricting the broad implementation of thorough treatment regimens and decelerating the sector's overall growth rate. Consequently, price sensitivity remains a critical challenge that could impede the widespread adoption of comprehensive management plans for animal gastroesophageal reflux disease, thereby slowing the expansion of the market.

Market Driver

The surge in global pet ownership and the trend of humanization are fundamentally transforming the demand for specialized veterinary therapeutics, especially for chronic ailments like gastroesophageal reflux disease. As owners increasingly regard companion animals as family members, they are more likely to seek immediate veterinary care for symptoms of distress, such as regurgitation or dysphagia, rather than ignoring them. This emotional connection drives higher utilization of diagnostic and pharmaceutical solutions, broadening the market for acid suppressants. Data from UK Pet Food's 'Pet Population 2024' report indicates that roughly 17.2 million households in the United Kingdom own a pet, accounting for 60 percent of the population, providing a vast and growing patient base for managing chronic digestive health conditions.

Additionally, the increasing prevalence of diet-induced and obesity-related reflux acts as a pivotal clinical catalyst for market growth, given that excess weight severely impairs gastrointestinal function. Obesity elevates intra-abdominal pressure, resulting in sphincter dysfunction and chronic acid reflux that requires ongoing pharmacological treatment. Despite this, early treatment is often hindered by a lack of owner awareness; the Association for Pet Obesity Prevention's '2023 National Pet Weight and Nutrition Survey' from May 2024 noted that only 17 percent of dog owners identified their pets as overweight, contrasting sharply with clinical prevalence. This gap highlights significant latent market potential as diagnostic awareness rises, further supported by the sector's strong economic foundation, evidenced by Zoetis reporting full-year 2023 revenue of $8.5 billion in 2024.

Market Challenge

The substantial expenses required for long-term veterinary management and specialized diagnostic procedures represent a major hurdle to the expansion of the Global Animal Gastroesophageal Reflux Disease Market. Accurate diagnosis often demands costly interventions like endoscopy or specialized pH monitoring, while effective treatment relies on the chronic administration of medications such as proton pump inhibitors. These financial requirements form a formidable barrier for price-sensitive pet owners, frequently resulting in the postponement of essential diagnostic screenings or the cessation of maintenance therapies, which ultimately reduces potential market revenue as segments of the pet population remain untreated.

This financial strain is reflected in recent industry metrics showing that escalating prices are influencing client behavior. According to the American Veterinary Medical Association, data analyzed in 2024 from thousands of practices indicated a 2.3% decline in patient visits compared to the previous year, a trend largely driven by rising service costs compelling budget-conscious owners to restrict veterinary visits. This decrease in clinical traffic directly impedes the market by reducing opportunities for veterinarians to diagnose and treat complex gastrointestinal disorders, thereby stalling the wider uptake of reflux disease therapeutics.

Market Trends

The adoption of Brachycephalic-Focused Treatment Protocols is swiftly altering clinical standards within the Global Animal Gastroesophageal Reflux Disease Market. Veterinarians are increasingly associating Brachycephalic Obstructive Airway Syndrome (BOAS) with hiatal hernias and chronic acid reflux, leading to specialized therapeutic regimens that integrate surgical airway correction with long-term acid suppression. This breed-specific approach is fueled by the enduring popularity of flat-faced dogs, which genetically demand significantly more gastrointestinal care than other breeds. As reported by the American Kennel Club in March 2024, French Bulldogs remained the most registered breed with 98,500 registrations, guaranteeing a steady stream of patients needing these targeted reflux management strategies.

Concurrently, the proliferation of Therapeutic Gastrointestinal Diets and Nutrition is transforming management strategies by emphasizing multimodal conservative therapy over sole reliance on pharmaceuticals. Industry leaders are vigorously expanding their offerings of highly digestible, low-fat prescription diets and microbiome-enhancing supplements aimed at alleviating reflux symptoms and boosting esophageal motility without the side effects associated with chronic medication. This movement mirrors a wider consumer shift toward functional wellness products serving as complementary treatments to standard proton pump inhibitors. According to Petfood Industry in February 2024, Purina Pro Plan Veterinary Supplement sales surged by 22.6% in 2023, highlighting the swift commercial adoption of nutritional interventions for digestive health.

Key Market Players

• Zoetis Inc.
• Merck & Co., Inc.
• Elanco Animal Health Inc.
• Ceva Sante Animale S.A.
• Boehringer Ingelheim International GmbH
• McNeil Consumer Pharmaceuticals Co.
• BioZyme, Inc.
• Annamaet Petfoods Inc.
• Hill's Pet Nutrition, Inc.
• Blue Buffalo Co., Ltd.

Report Scope

In this report, the Global Animal Gastroesophageal Reflux Disease Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Animal Gastroesophageal Reflux Disease Market, By Product

• Diagnostics
• Treatment
• Others

Animal Gastroesophageal Reflux Disease Market, By Animal Type

• Companion Animals
• Livestock Animals

Animal Gastroesophageal Reflux Disease Market, By Route of Administration

• Oral
• Injectable

Animal Gastroesophageal Reflux Disease Market, By Distribution Channel

• Veterinary hospitals & clinics
• Retail Pharmacies
• E-commerce

Animal Gastroesophageal Reflux Disease Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Animal Gastroesophageal Reflux Disease Market.

Available Customizations:

Global Animal Gastroesophageal Reflux Disease Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Animal Gastroesophageal Reflux Disease Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Diagnostics, Treatment, Others)
  • 5.2.2. By Animal Type (Companion Animals, Livestock Animals)
  • 5.2.3. By Route of Administration (Oral, Injectable)
  • 5.2.4. By Distribution Channel (Veterinary hospitals & clinics, Retail Pharmacies, E-commerce)
  • 5.2.5. By Region
  • 5.2.6. By Company (2025)
• 5.3. Market Map

6. North America Animal Gastroesophageal Reflux Disease Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Animal Type
  • 6.2.3. By Route of Administration
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Animal Type
      • 6.3.1.2.3. By Route of Administration
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Animal Type
      • 6.3.2.2.3. By Route of Administration
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Animal Gastroesophageal Reflux Disease Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Animal Type
      • 6.3.3.2.3. By Route of Administration
      • 6.3.3.2.4. By Distribution Channel

7. Europe Animal Gastroesophageal Reflux Disease Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Animal Type
  • 7.2.3. By Route of Administration
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Animal Type
      • 7.3.1.2.3. By Route of Administration
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Animal Type
      • 7.3.2.2.3. By Route of Administration
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Animal Type
      • 7.3.3.2.3. By Route of Administration
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Animal Type
      • 7.3.4.2.3. By Route of Administration
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Animal Gastroesophageal Reflux Disease Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Animal Type
      • 7.3.5.2.3. By Route of Administration
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Animal Gastroesophageal Reflux Disease Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Animal Type
  • 8.2.3. By Route of Administration
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Animal Type
      • 8.3.1.2.3. By Route of Administration
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Animal Type
      • 8.3.2.2.3. By Route of Administration
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Animal Type
      • 8.3.3.2.3. By Route of Administration
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Animal Type
      • 8.3.4.2.3. By Route of Administration
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Animal Gastroesophageal Reflux Disease Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Animal Type
      • 8.3.5.2.3. By Route of Administration
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Animal Gastroesophageal Reflux Disease Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Animal Type
  • 9.2.3. By Route of Administration
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Animal Type
      • 9.3.1.2.3. By Route of Administration
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Animal Type
      • 9.3.2.2.3. By Route of Administration
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Animal Gastroesophageal Reflux Disease Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Animal Type
      • 9.3.3.2.3. By Route of Administration
      • 9.3.3.2.4. By Distribution Channel

10. South America Animal Gastroesophageal Reflux Disease Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Animal Type
  • 10.2.3. By Route of Administration
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Animal Type
      • 10.3.1.2.3. By Route of Administration
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Animal Type
      • 10.3.2.2.3. By Route of Administration
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Animal Gastroesophageal Reflux Disease Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Animal Type
      • 10.3.3.2.3. By Route of Administration
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Animal Gastroesophageal Reflux Disease Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Zoetis Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Merck & Co., Inc.
• 15.3. Elanco Animal Health Inc.
• 15.4. Ceva Sante Animale S.A.
• 15.5. Boehringer Ingelheim International GmbH
• 15.6. McNeil Consumer Pharmaceuticals Co.
• 15.7. BioZyme, Inc.
• 15.8. Annamaet Petfoods Inc.
• 15.9. Hill's Pet Nutrition, Inc.
• 15.10. Blue Buffalo Co., Ltd.

16. Strategic Recommendations

17. About Us & Disclaimer